Table 3.
Clinical features of survivors and non-survivors in patients with COVID-19 with T2DM
| Survivor (n=89) | Non-survivor (n=49) | P value | |
| Pulmonary complications | |||
| ARDS, n (%) | 21/89 (23.06) | 46/49 (93.88) | <0.001 |
| Extrapulmonary complications | |||
| Acute cardiac injury, n (%) | 10/81 (12.35) | 37/49 (75.51) | <0.001 |
| Acute liver injury, n (%) | 0 | 1/45 (2.22) | 0.344* |
| Acute kidney injury, n (%) | 4/85 (4.71) | 29/48 (60.42) | <0.001 |
| Coagulopathy, n (%) | 9/81 (11.11) | 23/48 (47.92) | <0.001 |
| Hypoproteinemia, n (%) | 6/88 (6.82) | 23/49 (46.94) | <0.001 |
| Secondary infection, n (%) | 8/85 (9.41) | 10/42 (23.81) | 0.029 |
| Number of complications, n (%) | <0.001* | ||
| 0, n (%) | 45/76 (59.21) | 1/38 (2.63) | |
| 1, n (%) | 16/76 (21.05) | 4/38 (10.53) | |
| 2, n (%) | 13/76 (17.11) | 7/38 (18.42) | |
| 3, n (%) | 1/76 (1.32) | 11/38 (28.95) | |
| 4, n (%) | 1/76 (1.32) | 9/38 (23.68) | |
| 5, n (%) | 0 | 3/38 (7.89) | |
| 6, n (%) | 0 | 3/38 (7.89) |
The p value was calculated by χ2 test if not indicated. n indicates cases with available data.
*Fisher test.
ARDS, acute respiratory distress syndrome; T2DM, type 2 diabetes mellitus.